Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07573631 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy

StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 7 to 6
    • Start date changed from estimate of Apr 2026 to Apr 20, 2026
    • Secondary endpoints: details revised at 1 of 4 entries
    v3
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This open-label extension study aims to evaluate the long-term safety and tolerability of weekly BMN 351 infusions, as well as to assess the effect of BMN 351 on physical function, in participants with DMD who participated in the 351-201 study.
Trial Details
NCT Number NCT07573631
Lead Sponsor BioMarin Pharmaceutical
Conditions
(from sponsor)		 Duchenne Muscular Dystrophy (DMD)
Related terms Muscular Dystrophy, Duchenne
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov